Theravance Biopharma, Inc.
TBPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $64,381 | $57,424 | $51,346 | $55,311 |
| % Growth | 12.1% | 11.8% | -7.2% | – |
| Cost of Goods Sold | $0 | $40,621 | $63,392 | $193,657 |
| Gross Profit | $64,381 | $16,803 | -$12,046 | -$138,346 |
| % Margin | 100% | 29.3% | -23.5% | -250.1% |
| R&D Expenses | $37,643 | $46,344 | $70,074 | $201,548 |
| G&A Expenses | $64,874 | $65,352 | $59,073 | $0 |
| SG&A Expenses | $69,174 | $70,452 | $67,073 | $0 |
| Sales & Mktg Exp. | $4,300 | $5,100 | $8,000 | $0 |
| Other Operating Expenses | $4,513 | -$43,958 | -$57,236 | -$82,110 |
| Operating Expenses | $111,330 | $72,838 | $79,911 | $119,438 |
| Operating Income | -$46,949 | -$56,035 | -$91,957 | -$257,784 |
| % Margin | -72.9% | -97.6% | -179.1% | -466.1% |
| Other Income/Exp. Net | $2,335 | $6,766 | -$858 | -$7,438 |
| Pre-Tax Income | -$44,614 | -$49,269 | -$92,815 | -$265,222 |
| Tax Expense | $11,804 | $5,924 | $9 | -$151 |
| Net Income | -$56,418 | -$55,193 | $872,132 | -$199,426 |
| % Margin | -87.6% | -96.1% | 1,698.5% | -360.6% |
| EPS | -1.15 | -1 | -1.26 | -2.87 |
| % Growth | -15% | 20.6% | 56.1% | – |
| EPS Diluted | -1.15 | -1 | -1.26 | -2.87 |
| Weighted Avg Shares Out | 48,847 | 55,303 | 73,591 | 69,461 |
| Weighted Avg Shares Out Dil | 48,847 | 55,303 | 73,591 | 69,461 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,881 | $9,116 | $8,545 | $1,109 |
| Interest Expense | $2,546 | $2,350 | $6,369 | $8,547 |
| Depreciation & Amortization | $3,615 | $2,001 | $3,035 | $4,812 |
| EBITDA | -$38,453 | -$51,648 | -$76,084 | -$232,830 |
| % Margin | -59.7% | -89.9% | -148.2% | -420.9% |